"""
Question: 1101 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. Table 2 shows the correlation on resistance mutations (Sanger sequencing) detected at RAL failure in plasma and on proviral DNA, after a median period of 48 months of being undetectable.

Rationale: The study describes newly collected and analyzed patient data (n=7) and presents new results comparing plasma failure genotypes with later proviral DNA genotypes, indicating the paper reports original, previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: For Sanger sequencing, we used a bidirectional sequencing protocol and the Thermo Sequenase Dye Primer Manual Cycle Sequencing Kit (Affymetrix USB), which was optimized for the TruGene/OpenGene DNA sequencing system (SIEMENS); sequencing primers were ... allowing to sequence 414 nucleotides in the Integrase region, covering positions 40 to 178. Ultra Deep Sequencing (UDS) was done using an HIV-1 UDS prototype (Roche diagnostics) and the 454 GS Junior (Roche 454 Life Sciences Branford, CT).

Rationale: The methods describe generation of HIV-1 integrase sequence data by Sanger and next-generation sequencing, and the results/tables report per-patient mutation profiles derived from these sequences, meaning the paper reports HIV sequences.

Answer: Yes
"""

"""
Question: 1103 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. This was a retrospective, non-interventional study, and patient information was anonymized and de-identified prior to analysis.

Rationale: The study was conducted on clinical specimens from patients without laboratory passaging or experimental evolution; therefore, it did not involve in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: For Sanger sequencing, we used a bidirectional sequencing protocol ... allowing to sequence 414 nucleotides in the Integrase region. Ultra Deep Sequencing (UDS) was done ... and interpreted by DeepChek®- VIH software.

Rationale: The methods describe only genotypic sequencing (Sanger and UDS) without any phenotypic susceptibility assays; no IC values or drug susceptibility assays are reported.

Answer: No
"""

"""
Question: 2101 

Evidence: All data supporting our findings is contained within the manuscript. The obtained sequences were aligned and combined using OpenGene Geneobjects software, and fasta sequences were interpreted Stanford HIV Database Versión 7.0.

Rationale: The paper states data are contained within the manuscript and describes sequence interpretation but does not provide any GenBank accession numbers.

Answer: No
"""

"""
Question: 2102 

Evidence: All data supporting our findings is contained within the manuscript. The obtained sequences were aligned and combined using OpenGene Geneobjects software, and fasta sequences were interpreted Stanford HIV Database Versión 7.0.

Rationale: There are no accession numbers reported for any sequenced isolates, clinical or otherwise.

Answer: No
"""

"""
Question: 2103 

Evidence: All data supporting our findings is contained within the manuscript. The obtained sequences were aligned and combined using OpenGene Geneobjects software, and fasta sequences were interpreted Stanford HIV Database Versión 7.0.

Rationale: No GenBank accession numbers are provided anywhere in the manuscript.

Answer: NA
"""

"""
Question: 2202 

Evidence: Table 2 shows the correlation on resistance mutations (Sanger sequencing) detected at RAL failure in plasma and on proviral DNA, after a median period of 48 months of being undetectable. Sanger sequencing correctly identified all the secondary mutations.

Rationale: Table 2 provides per-patient lists of primary, accessory, and polymorphism mutations at failure and in proviral DNA, indicating mutation lists for individual sequenced isolates.

Answer: Yes
"""

"""
Question: 2301 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. All the patients were infected by HIV-1 B subtypes.

Rationale: The manuscript explicitly states the virus species studied is HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. Detailed information on baseline characteristics is shown in Table 1.

Rationale: It is explicitly stated that all patients were infected with subtype B viruses.

Answer: Subtype B
"""

"""
Question: 2303 

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. Integrase was amplified using a nested-PCR.

Rationale: The study sequenced the HIV-1 integrase gene region.

Answer: Integrase (pol)
"""

"""
Question: 2304 

Evidence: For Sanger sequencing, we used ... allowing to sequence 414 nucleotides in the Integrase region, covering positions 40 to 178. Table 2 shows the correlation on resistance mutations ... detected at RAL failure in plasma and on proviral DNA.

Rationale: Integrase is part of the HIV-1 pol gene; thus, the paper reports results from pol sequences (integrase region).

Answer: Yes
"""

"""
Question: 2401 

Evidence: All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. The Ethics Committee of the San Cecilio Hospital approved the study.

Rationale: The paper specifies that the patients (and hence sequences) originated from Spain.

Answer: Spain
"""

"""
Question: 2402 

Evidence: Detailed information on baseline characteristics is shown in Table 1. The median time (IQR) between previous failure to RAL and the study on proviral DNA was 48 (29–53) months.

Rationale: Table 1 lists the dates of failure for plasma sequencing as occurring in 2009, 2010, 2011, and 2012; the proviral DNA sampling occurred 29–56 months later, but specific years for those samples are not explicitly stated in the text.

Answer: 2009, 2010, 2011, 2012
"""

"""
Question: 2502 

Evidence: For Sanger sequencing, we used a bidirectional sequencing protocol ... optimized for the TruGene/OpenGene DNA sequencing system (SIEMENS). The obtained sequences were aligned and combined using OpenGene Geneobjects software.

Rationale: The methods clearly detail the use of Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Ultra Deep Sequencing (UDS) was done using an HIV-1 UDS prototype (Roche diagnostics) and the 454 GS Junior (Roche 454 Life Sciences Branford, CT). Once UDS was performed, sequences were exported by AVA ... and interpreted by DeepChek®- VIH software.

Rationale: UDS on the 454 GS Junior is an NGS technology.

Answer: Yes
"""

"""
Question: 2504 

Evidence: Integrase was amplified using a nested-PCR. For Sanger sequencing, we used a bidirectional sequencing protocol ... allowing to sequence 414 nucleotides in the Integrase region.

Rationale: The workflow involved direct PCR amplification and population (bulk) sequencing; there is no mention of cloning prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient. Sanger sequencing correctly identified all the secondary mutations.

Rationale: The paper refers to population (bulk) sequencing and UDS; it does not describe single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: Integrase was amplified using a nested-PCR. For Sanger sequencing, we used a bidirectional sequencing protocol ... and Ultra Deep Sequencing (UDS) was done ... using the 454 GS Junior.

Rationale: No molecular cloning steps are described; only PCR amplification and direct sequencing were used.

Answer: No
"""

"""
Question: 2601 

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. Table 2 shows the correlation on resistance mutations ... detected at RAL failure in plasma and on proviral DNA.

Rationale: The paper reports plasma RNA genotypes at the time of raltegravir failure.

Answer: Yes
"""

"""
Question: 2602 

Evidence: After an average (IQR) time of 48 months (29–53), Integrase resistance mutations in proviral DNA were studied. Peripheral Blood Mononuclear Cells (PBMC) were separated ... and used for DNA extraction.

Rationale: The study sequenced integrase from proviral DNA in PBMCs.

Answer: Yes
"""

"""
Question: 2603 

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1.

Rationale: Since each of the 7 patients had a plasma genotype at failure, there were 7 plasma sequencing samples.

Answer: 7
"""

"""
Question: 2604 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. After an average (IQR) time of 48 months (29–53), Integrase resistance mutations in proviral DNA were studied.

Rationale: Proviral DNA sequencing was performed for all 7 patients.

Answer: 7
"""

"""
Question: 2605 

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. Table 2 shows the correlation on resistance mutations ... detected at RAL failure in plasma and on proviral DNA.

Rationale: Sequencing at the time of RAL failure indicates active replication with detectable plasma virus; thus some sequences were obtained from individuals with active HIV replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: After an average (IQR) time of 48 months (29–53), Integrase resistance mutations in proviral DNA were studied. Peripheral Blood Mononuclear Cells (PBMC) were separated ... and used for DNA extraction.

Rationale: The paper explicitly reports sequencing from proviral DNA reservoirs in PBMCs.

Answer: Yes
"""

"""
Question: 2701 

Evidence: All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. Detailed information on baseline characteristics is shown in Table 1.

Rationale: All participants were adults; there is no indication of infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: We have performed a pilot, observational, retrospective, non interventional study. This was a retrospective, non-interventional study, and patient information was anonymized and de-identified prior to analysis.

Rationale: The study was observational and retrospective, not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: We have performed a pilot, observational, retrospective, non interventional study. This was a retrospective, non-interventional study, and patient information was anonymized and de-identified prior to analysis.

Rationale: Because no participants were in a clinical trial, it cannot be the case that all were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. A genotypic viral Integrase region study was available for each patient at the moment of RAL failure.

Rationale: The cohort size was 7 and each had sequencing.

Answer: 7
"""

"""
Question: 3102 

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. After an average (IQR) time of 48 months (29–53), Integrase resistance mutations in proviral DNA were studied.

Rationale: All individuals had sequencing at failure and later proviral DNA sequencing.

Answer: Yes
"""

"""
Question: 4101 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen. The use of DTG to salvage patients who have developed resistance to RAL has been well studied and documented.

Rationale: All individuals were ART-experienced with prior INSTI exposure and failure; none were ART-naive.

Answer: No
"""

"""
Question: 4102 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen. They were successfully salvaged and had reached viral suppression.

Rationale: Prior failure to raltegravir indicates prior ARV exposure.

Answer: Yes
"""

"""
Question: 4103 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen. A genotypic viral Integrase region study was available for each patient at the moment of RAL failure.

Rationale: The study includes only ART-experienced individuals; there are no ART-naive participants.

Answer: No
"""

"""
Question: 4104 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients ... all with a history of previous failure to a RAL containing regimen. They were successfully salvaged and had reached viral suppression.

Rationale: All individuals were ART-experienced; therefore, there were no ART-naive individuals.

Answer: 0
"""

"""
Question: 4105 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients ... all with a history of previous failure to a RAL containing regimen. Detailed information on baseline characteristics is shown in Table 1.

Rationale: Aside from noting prior RAL failure and subsequent suppression, the paper does not provide complete ART regimen histories for each individual.

Answer: No
"""

"""
Question: 4201 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients ... all with a history of previous failure to a RAL containing regimen. Table 2 shows the correlation on resistance mutations ... detected at RAL failure in plasma and on proviral DNA.

Rationale: The paper focuses on resistance after treatment failure, not on prevalence of transmitted drug resistance.

Answer: No
"""

"""
Question: 4202 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients ... all with a history of previous failure to a RAL containing regimen. Table 2 shows the correlation on resistance mutations ... detected at RAL failure in plasma and on proviral DNA.

Rationale: The cohort is not pretreatment; there is no analysis of pretreatment (baseline, ART-naive) resistance prevalence.

Answer: No
"""

"""
Question: 4301 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients ... all with a history of previous failure to a RAL containing regimen. In our study, we have hypothesized that proviral DNA may show the history of mutations ... in patients who are currently undetectable and candidates to simplification to a Dolutegravir containing regimen.

Rationale: The paper documents prior exposure to the integrase inhibitor raltegravir and discusses potential simplification to dolutegravir, indicating the INSTI drug class.

Answer: Integrase inhibitors (raltegravir; consideration of dolutegravir)
"""

"""
Question: 4302 

Evidence: ... all with a history of previous failure to a RAL containing regimen. ... candidates to simplification to a Dolutegravir containing regimen.

Rationale: These are integrase inhibitors (RAL and DTG), confirming that individuals received INSTIs.

Answer: Yes
"""

"""
Question: 4303 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients ... all with a history of previous failure to a RAL containing regimen. Table 2 shows the correlation on resistance mutations ... in the Integrase.

Rationale: The manuscript does not report that participants received protease inhibitors; only integrase inhibitor exposure is described.

Answer: No
"""

"""
Question: 4304 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients ... all with a history of previous failure to a RAL containing regimen. They were successfully salvaged and had reached viral suppression.

Rationale: The paper does not detail the specific regimens for each individual, so it cannot be determined whether all received the same ART.

Answer: NA
"""

"""
Question: 4305 

Evidence: ... all with a history of previous failure to a RAL containing regimen. The use of DTG to salvage patients who have developed resistance to RAL has been well studied and documented.

Rationale: Prior RAL failure means they were not INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: ... all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. The VIKING study evaluated Dolutegravir dosing ... [context of salvage after INSTI resistance].

Rationale: Each participant had at least one failed regimen (RAL-containing) and then a salvage regimen, indicating more than one ART regimen for all individuals.

Answer: 7
"""

"""
Question: 4404 

Evidence: We have performed a pilot, observational, retrospective, non interventional study ... They were successfully salvaged and had reached viral suppression.

Rationale: The exact number of distinct regimens per individual is not provided beyond noting failure and salvage; more than two regimens cannot be determined.

Answer: NA
"""

"""
Question: 4405 

Evidence: We have performed a pilot, observational, retrospective, non interventional study ... all with a history of previous failure to a RAL containing regimen. They were successfully salvaged and had reached viral suppression.

Rationale: The number of regimens per person is not detailed, so whether all received the same number of regimens cannot be determined.

Answer: NA
"""

"""
Question: 4406 

Evidence: ... all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. Table 2 shows the correlation on resistance mutations ... detected at RAL failure in plasma and on proviral DNA.

Rationale: Because each person experienced failure and then salvage (implying a second regimen), not all received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: In our study, we have hypothesized that proviral DNA may show the history of mutations ... in patients who are currently undetectable and candidates to simplification to a Dolutegravir containing regimen. The use of DTG to salvage patients who have developed resistance to RAL has been well studied and documented.

Rationale: The paper discusses DTG as a potential option but does not report how many in this cohort actually received DTG.

Answer: NA
"""

"""
Question: 4502 

Evidence: We have performed a pilot, observational, retrospective, non interventional study ... Table 2 shows ... Integrase ... The manuscript does not describe protease inhibitor treatments.

Rationale: There is no report of darunavir use in this cohort.

Answer: NA
"""

"""
Question: 5101 

Evidence: At failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). Sanger sequencing correctly identified all the secondary mutations.

Rationale: Table 2 shows that across the 7 individuals, each had at least one primary (N155H) or accessory INSTI-resistance mutation at failure; therefore, all 7 had one or more drug resistance mutations.

Answer: 7
"""

"""
Question: 5102 

Evidence: At failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient.

Rationale: Considering primary and accessory INSTI-resistance mutations per Table 2, all 7 individuals had at least one INSTI-resistance mutation either at failure and/or in proviral DNA (with UDS for patient 6).

Answer: 7
"""

"""
Question: 5103 

Evidence: For Sanger sequencing, we used ... allowing to sequence 414 nucleotides in the Integrase region, covering positions 40 to 178. Integrase was amplified using a nested-PCR.

Rationale: The study sequenced only the integrase region; no reverse transcriptase or TDF-associated mutations were evaluated or reported.

Answer: NA
"""

"""
Question: 5104 

Evidence: At failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient.

Rationale: Table 2 lists the specific INSTI-resistance mutations observed, including the primary mutation N155H and accessory mutations such as T97A, L74I, G163R, and V151I.

Answer: N155H; accessory mutations including T97A, L74I, G163R, and V151I
"""

"""
Question: 6101 

Evidence: For Sanger sequencing, we used a bidirectional sequencing protocol ... allowing to sequence 414 nucleotides in the Integrase region. Ultra Deep Sequencing (UDS) was done using ... the 454 GS Junior.

Rationale: Only genotypic sequencing was performed; no phenotypic susceptibility testing methods were used.

Answer: NA
"""

"""
Question: 6102 

Evidence: For Sanger sequencing, we used a bidirectional sequencing protocol ... Ultra Deep Sequencing (UDS) was done ... and interpreted by DeepChek®- VIH software.

Rationale: The paper does not report IC values such as IC50 or IC90.

Answer: No
"""

"""
Question: 6103 

Evidence: For Sanger sequencing, we used ... Ultra Deep Sequencing (UDS) was done ... The obtained sequences were ... interpreted Stanford HIV Database.

Rationale: No phenotypic assays were performed; therefore, no IC50 fold change values are reported.

Answer: No
"""

"""
Question: 6104 

Evidence: Ultra Deep Sequencing (UDS) was done using an HIV-1 UDS prototype ... For Sanger sequencing, we used a bidirectional sequencing protocol.

Rationale: No phenotypic susceptibility assay is described, only sequencing; hence there is no phenotypic assay to name.

Answer: NA
"""

"""
Question: 6105 

Evidence: Table 2 shows the correlation on resistance mutations ... detected at RAL failure in plasma and on proviral DNA. Sanger sequencing correctly identified all the secondary mutations.

Rationale: The study reports genotypic data; replication capacity measurements are not presented.

Answer: No
"""

"""
Question: 6106 

Evidence: We have performed a pilot, observational, retrospective, non interventional study ... Integrase resistance mutations in proviral DNA were studied. For Sanger sequencing, we used ... and Ultra Deep Sequencing (UDS) was done ...

Rationale: No phenotypic susceptibility testing was done; therefore, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. Integrase resistance mutations in proviral DNA were studied.

Rationale: The study analyzed clinical isolates from patients; it did not create site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. This was a retrospective, non-interventional study, and patient information was anonymized and de-identified prior to analysis.

Rationale: No in vitro passage experiments were performed; all data came from patient-derived samples.

Answer: No
"""